Clenbuterol: a new toxic substance in paediatrics.
Acidosis
/ chemically induced
Adolescent
Adrenergic beta-Agonists
/ toxicity
Chest Pain
/ diagnosis
Clenbuterol
/ toxicity
Diagnosis, Differential
Electrocardiography
/ methods
Emergency Service, Hospital
Female
Humans
Hyperglycemia
/ chemically induced
Hypokalemia
/ chemically induced
Hypophosphatemia
/ chemically induced
Nausea
/ diagnosis
Tachycardia, Sinus
/ chemically induced
Treatment Outcome
Tremor
/ diagnosis
drug misuse (including addiction)
paediatrics
paediatrics (drugs and medicines)
poisoning
toxicology
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
12 Mar 2020
12 Mar 2020
Historique:
entrez:
15
3
2020
pubmed:
15
3
2020
medline:
25
11
2020
Statut:
epublish
Résumé
A 13-year-old girl presented to the emergency department with acute onset of chest pain, nausea and tremor. The patient denied drug ingestion, and urine toxicology was negative. ECG demonstrated sinus tachycardia, prolonged QTc (541 ms) and ST depression. Laboratory testing demonstrated metabolic acidosis, hypokalaemia, hypophosphataemia and hyperglycaemia. She was commenced on continuous cardiac monitoring and treated with intravenous fluids and electrolyte replacement. Presenting features and laboratory abnormalities resolved within 48 hours. The National Poisons Information Service and Clinical Biochemistry were integral to her management, advising the clinical team on the likeliest aetiology. Five weeks after discharge, urine toxicology, using mass spectrometry, identified clenbuterol. Clenbuterol is an oral β2-agonist with anabolic and lipolytic effects that is misused as a performance and image enhancing drug. Clinicians must be aware of the increasing availability of these drugs and their potential for causing harm in children and adolescents.
Identifiants
pubmed: 32169984
pii: 13/3/e233180
doi: 10.1136/bcr-2019-233180
pmc: PMC7069258
pii:
doi:
Substances chimiques
Adrenergic beta-Agonists
0
Clenbuterol
XTZ6AXU7KN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Circ J. 2005 Sep;69(9):1144-6
pubmed: 16127201
Med J Aust. 2009 Jan 5;190(1):41-3
pubmed: 19120009
J Emerg Med. 2019 Oct;57(4):e105-e108
pubmed: 31493966
Am J Emerg Med. 2014 Jan;32(1):111.e3-4
pubmed: 24079989
Emerg Med J. 2002 Jan;19(1):31-4
pubmed: 11777868
Am J Ther. 2013 May-Jun;20(3):311-4
pubmed: 21317628
Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):182-187
pubmed: 29498199
Am J Emerg Med. 2016 Aug;34(8):1739.e5-7
pubmed: 26873408
J Med Toxicol. 2007 Jun;3(2):56-60
pubmed: 18072161
Med J Aust. 2014 Mar 3;200(4):219-21
pubmed: 24580525
J Pharm Pract. 2020 Jun;33(3):386-389
pubmed: 30669920
Res Social Adm Pharm. 2019 Aug;15(8):949-952
pubmed: 31303195